A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program.
- DOI
- 10.1093/crocol/otag103
- Published
- 2026 Oct
- Container
- Crohn's & colitis 360
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/crocol/otag103,
title = {A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson \& Johnson's BIOADVANCE program.},
author = {Targownik L and Pone E and Latour MG and Boyerahmadi K and Yang H and Ling J and Tehrani A and Golden S and Marshall JK},
year = {2026},
journal = {Crohn's \& colitis 360},
doi = {10.1093/crocol/otag103},
url = {https://doi.org/10.1093/crocol/otag103}
}RIS
TY - JOUR TI - A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program. AU - Targownik L AU - Pone E AU - Latour MG AU - Boyerahmadi K AU - Yang H AU - Ling J AU - Tehrani A AU - Golden S AU - Marshall JK PY - 2026 JO - Crohn's & colitis 360 DO - 10.1093/crocol/otag103 UR - https://doi.org/10.1093/crocol/otag103 ER -
APA
L, T., E, P., MG, L., K, B., H, Y., J, L., A, T., S, G., & JK, M. (2026). A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program.. Crohn's & colitis 360. https://doi.org/10.1093/crocol/otag103
Source records
- pubmed · retrieved 2026-11-10T14:38:43.753Z